Background. Cutaneous leishmaniasis (CL) is a disfiguring but not life-threatening disease. Because antileishmanial drugs are potentially toxic, the World Health Organization (WHO) recommends simple wound care or local therapy as first-line treatment, followed or replaced by systemic therapy if local therapy fails or cannot be performed.
sometimes with a toxic drug lot [3] [4] [5] [6] . Systemic administration of reference agents such as pentavalent antimony, pentamidine, formulations of amphotericin B, or oral miltefosine can indeed cause systemic toxicity [3, 5, [7] [8] [9] [10] [11] [12] [13] . International and national treatment guidelines for CL thus favor options that increase the likelihood of rapid healing of CL lesions with the smallest risk of severe adverse events [14] [15] [16] . Unspecific wound care followed by patience, a cheap treatment devoid of toxicity, has been recommended [15, 16] , but the proportion of patients who can actually benefit from it has not been determined and may be low. Spontaneous healing rates in patients with CL are indeed highly variable (0%-71%, [17] ) and furthermore influenced by the infecting species. Simple wound care is not an optimal option in patients with disfiguring lesions [14] [15] [16] . The implementation of local antileishmanial therapy is logistically demanding and dependent on lesion topography. For example, the local therapy currently recommended in France requires the sequential application of cryotherapy and intralesional injections of antimony (Cryo + IlSb). The procedure is highly effective [18] [19] [20] but is relatively painful and difficult to apply to "complex" lesions (ie, those located on the ears, eyelids, or lips, or those close to small joints). Additionally, it can only be performed by trained physicians who have access to liquid nitrogen.
Not least, no systemic therapeutic option is effective and applicable in all forms of CL [21] . Although high-dose oral fluconazole was effective in Iran [22] and Brazil [23] , observance and cost may limit its impact. Miltefosine has been equivalent [24] or superior [25] to systemic Glucantime in some settings, but its teratogenicity and long half-life are issues for wide-scale use. Considering the limitations of the different options and the variable severity of CL, recent guidelines recommend using wound care without antileishmanial therapy whenever possible, then local therapy whenever possible, and finally systemic therapy if local therapy fails or cannot be performed ( Figure 1 ) [15, 16] . This stepwise process is intended to limit the risk of severe adverse events and reduce costs while preserving efficacy. It integrates many parameters, including the size, aspect, topography, and number of lesions, the suspected or proven infecting species, and the patient's age and general health status ( Figure 1 ) [26] . These treatment guidelines are based on clinical experience and analyses of published data [16, 27] but have not been evaluated in clinical practice.
In the present report, we analyzed data collected by experts with the French leishmaniasis reference center (NRCL); these experts provide treatment advice to physicians attending patients with leishmaniasis. Data regarding 135 consecutive CL patients over 6 years were captured and used to determine the applicability of the recommended approach. Specifically, we focused on determining-in the general population of CL patients-the proportion of patients who could be treated without systemic therapy, and the proportion of positive outcome in each treatment category (ie, simple wound care, local therapy, and systemic therapy).
MATERIALS AND METHODS

Patients, Medical Care, and Data Collection
From 2006 through 2011, data were collected each time treatment advice was sought from an expert at the NRCL. Data from patients with parasitologically confirmed tegumentary leishmaniasis were collected. Diagnostic procedures were not modified by the process, expert treatment advice was part of normal medical care, and data collection was in the context of national health surveillance. Patients were informed of the process by their attending physician using a procedure common to all French National Reference Centers (http://www.parasitologie. univ-montp1.fr/conseil.htm) and gave their oral consent for data collection. Mention of this consent was written in the medical chart.
Parasitological Confirmation of Diagnosis: Species Identification
Parasitological diagnosis was performed and analyzed as previously described [17, 28] by lesion scraping, biopsy, or aspirate followed by direct examination of Giemsa-stained smears, histological analysis of Hematein-Eosin-Safran-or Giemsastained tissue sections, culture, or polymerase chain reaction (PCR). Whenever possible, tissue samples and aliquots of positive cultures were sent to the NRCL for confirmation and species identification using a multilocus sequence typing approach based on the analysis of 7 single-copy coding DNA sequences (C. Ravel, personal data).
Physicians
Attending physicians were general practitioners, dermatologists, infectious diseases specialists, parasitologists, or pediatricians who were aware of the expert advice available from the NRCL.
Experts, Guidelines, Formalized Process for Treatment Advice, and Outcome Treatment advice to physicians was provided by 2 specialists (L.L, P.A.B.) with expertise in leishmaniasis therapy [17, 29, 30] , who furthermore participated in the establishment of the French national guidelines. The availability of the experts was permanent via a mobile phone. Advice was generally provided within 48 hours, most often during the first interaction. Guidelines were initially based on expert reviews published in French [30, 31] or in English [14, 32, 33] . The content of the published guidelines is recapitulated as an algorithm in Figure 1 ; treatment decisions were made according to this algorithm. The only important modification between 2006 and 2011 was the removal of oral fluconazole as a first-line option for the treatment of Leishmania major CL (at end 2006), when results obtained in French travelers [17] did not confirm the previous encouraging results in L. major CL from Saudi Arabia [34] . In the context of the treatment advice embedded in the national surveillance program, we optimized data collection as follows. During initial interactions with attending physicians, information essential for an accurate therapeutic decision was collected on a standardized NRCL form by the experts. This included demographics, travel history, risk factors, medical history, physical examination including lesion topography, aspect, and size, and available laboratory parameters. Data from parasitological tests performed to confirm diagnoses and determine infecting Leishmania species were also captured. The infecting Leishmania species may influence treatment choice and treatment outcome; thus, the experts indicated what was the presumptive infecting species based on epidemiological and clinical data and used this information to immediately select the treatment option consistent with guidelines. Six to 8 weeks after the advice had been provided, the attending physician was contacted by one of the experts and asked to provide complementary information on species identification, treatment actually administered, disease outcome (including lesion size and lesion healing according to a harmonized criterion used in recent cohort studies and clinical trials [17, 28] ), and occurrence of side effects related to any utilized drugs. The quality of data collection was checked by retrieving available written information (on medical charts or reports collected during follow-up) to compare it with all available items in the database.
Database and Data Analysis
The employed database was approved by the French national commission for information technology rights. Variables were summarized as frequencies and percentages, means and standard deviations, or medians and interquartile ranges (IQR), as appropriate, then compared using the χ 2 test when appropriate.
Concordance between suspected and confirmed species was analyzed using the κ statistic. Physicians' treatment options were compared to the expert advice using χ 2 tests or Fisher exact test when appropriate. Statistical analysis was performed using Intercooled Stata software, version 10 for Windows. All reported P values are 2-tailed.
RESULTS
Characteristics of Patients and Lesions
Of 168 patients for whom physicians requested expert advice from the NRCL, 135 had parasitologically confirmed tegumentary leishmaniasis. This represents 34% of the 402 patients with CL reported to the NRCL from metropolitan France during the same period. Figure 2 ) occurred in 28 patients (21% of all cases), 26 of whom were travelers and 2 of whom lived in endemic areas. Analysis of lesion topography ( Figure 3) showed that 83% and 89% of lesions were located in body areas where local injections and application of ointments, respectively, can be performed.
Characteristics of Physicians Seeking Expert Advice
Ninety physicians asked for advice: 65 used the system once, 25 more than once (range, 2-7); 9% were general practitioners, 51% dermatologists, 19% infectious diseases specialists, 16% parasitologists, and 5% from other health provider categories.
Parasitological Confirmation and Species Determination
Parasitological diagnosis was confirmed by a single method (smear, histology, culture, or PCR) in 65 patients (48%) and by 2 or more methods in 70 (52%). The infecting species was identified in 70 of the 135 patients (52%). The infecting species predicted by the expert (based on epidemiological and clinical data) before formal parasitological identification was confirmed by PCR in patients infected in the Old World in 96% of cases with a κ of 0.93 (95% CI, 0.92-1.00), and in patients infected in the New World in 74% of cases with a κ of 0.59 (95% CI, 0.45-0.82; Supplementary Table 2) .
Treatment Outcome
A detailed analysis focused on the main treatment options (Table 1) was performed on 109 medical charts that contained outcome data at least at day 42 through day 60. All patients included in this detailed analysis had been treated according to the recommended algorithm ( Figure 1 ). The 26 patients not included in this detailed analysis had been managed with options not included in the recommendations (14 patients), or had received oral fluconazole (when fluconazole was still recommended as a first-line option; 6 patients), or had been lost to follow-up (6 patients). Twenty-three (92%) of the 25 patients receiving simple wound care had positive outcomes at days 42-60. As expected from the algorithm used (Figure 1) , none of these patients had underlying immunodepression and most were infected with L. major or Leishmania mexicana (84%; ). Some patients required additional courses of treatment, but all were finally cured (excluding the 6 lost to follow-up). Of 10 evaluable immunosuppressed patients, 3 were treated locally and cured, whereas 3 of 7 patients receiving systemic treatment were cured.
Adverse Events
Of the 50 patients receiving systemic therapy, 15 (30%) experienced at least 1 systemic adverse event (AE). All systemic AEs occurred in patients receiving systemic antimony (7 of 14), systemic liposomal amphotericin B (7 of 21), or miltefosine (1 of 1; Table 2 ). The grading according to the National Cancer Institute Common Terminology Criteria for Adverse Events definition (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_ 2010-06-14_QuickReference_5×7.pdf) was 1 (mild) = 5 patients; 2 (moderate) = 8 patients; 4 (life threatening) = 2 patients. In 14 patients receiving systemic antimony, the median age was 50.7 years (IQR, 44.1-55.7 years) for those experiencing a systemic AE, and 41.4 years (IQR, 34.6-47.4 years) for those without systemic AE. Only 3 (6%) AEs (all mild) were reported in the 47 patients receiving Cryo + IlSb.
DISCUSSION
Our analysis, based on a nationwide, centralized, referral treatment program, shows that a majority of travelers with CL can be treated locally rather than systemically, and that this guideline-based approach is generally associated with a positive outcome. More than half of the patients (62%) were indeed initially managed without systemic therapy, either by simple wound care (19%), by Cryo + IlSb (41%), or by topical therapy with ointments. Cure rates at days 42-60 in patients with complete charts were 92% for simple wound care and 79% for Cryo + IlSb. Relatively few patients had been infected in the New World (21%), and 56% of all patients were infected with L. major. Our analysis was thus partially skewed toward a simple wound care approach. Yet, the high proportion of positive outcomes in this subgroup (92%) suggests that the criteria used to recommend this option accurately predict patients who will self-cure; this furthermore included several patients who were not infected with L. major. When appropriately selected, and informed about the lack of risk for themselves and others, a vast majority of patients followed this approach until cure. Predictably, no AEs were reported in this group. Conversely, AEs occurred in 15 (30%) of the 50 patients receiving systemic therapy. None of these AEs resulted in longterm sequelae but treatment was prematurely interrupted in 11 of these patients. We emphasize that these decisions to discontinue treatment were based on close monitoring of clinical and laboratory parameters. This evokes the question of what would have been the outcome if laboratory parameters had been less easily accessible, a frequent situation in several CL-endemic countries where systemic antimony, and possibly other systemic regimens, are administered with no systematic follow-up of laboratory findings. In a recent analysis of systemic antimony toxicity in 67 travelers without preexisting morbidity, close follow-up of laboratory data was key for a timely suspension of treatment in 6 patients [38] . Recent observations in Tunisia suggest that antimony-induced severe adverse events affecting the kidney or liver are not exceptional [39] . Taken together, these observations reinforce the current assertion that the benefit-risk ratio of systemic anti-leishmanial therapy for CL requires cautious evaluation in the general population of patients. In 14 patients receiving systemic antimony, the median age was 50.7 years (IQR, 44.1-55.7 years) for those experiencing a systemic AE, and 41.4 years (IQR, 34.6-47.4 years) for c Drug rash with eosinophilia and systemic symptoms. This medical history has been reported elsewhere [37] .
Expert Advice in Cutaneous Leishmaniasis • CID 2013:57 (1 August) • 377 those without systemic AE. The risk of mortality under systemic antimony for visceral leishmaniasis is significantly greater in patients older than 45 years [40, 41] . Although based on a limited number of patients, our observation suggests that older age may also be associated with an increased risk of antimonyinduced systemic AE in patients with CL, either directly or as a surrogate for preexisting comorbidities. Whereas the population of volunteers in many clinical trials of systemic antimony has been markedly biased toward young adult males without preexisting morbidity [32, [42] [43] [44] [45] , our population encompassed a broad spectrum of clinical situations, including prior antileishmanial therapy (24%), preexisting comorbidities (16%), and immunosuppression (9%; Supplementary Table 1) . Our data also suggest that in older patients with frequent comorbidities and/or large lesions (situation 3 in the algorithm), infection with all species (including L. major) may be difficult to cure, thus justifying a specific management and adapted research strategies. International initiatives (eg, LeishMan European network, http://www.tropnet.net/index.php?id=103) will allow for a powerful determination of factors associated with positive outcome and help further improve treatment algorithms and recommendations. Limiting the proportion of patients receiving systemic therapy is likely a simple way of reducing therapeutic risk. AEs were infrequent in the 47 patients receiving Cryo + IlSb; those that did occur were mild. Although the proportion of patients selected for local therapy (including simple wound care) may be smaller in countries/areas where L. major is less prevalent, we nonetheless believe that the general stepwise approach analyzed here will be useful elsewhere. Indeed it provides a simple, harmonized strategy for general treatment decisions in CL, based on a robust equilibrium between the benefits and the risks of available options. More than two-thirds of the patients infected with L. infantum, L. aethiopica, or L. tropica were managed without systemic therapy, and the cure rate in this group was similar to that of the L. major-infected patients (83% vs 82%). Confirmation of this finding in larger cohorts of patients is needed. Although traditionally limited to systemic therapy [32] , recommendations and investigations for the treatment of New World cutaneous leishmaniasis have progressively included local therapy [26, [46] [47] [48] . This decision is largely based on a detailed analysis of the relatively small risk of evolution to mucocutaneous leishmaniasis outside of Bolivia [49] , and on the rise of new options to treat mucocutaneous leishmaniasis if it occurs [12, 15, 16, 50] . Four of the 19 patients (21%) with suspected or proven L. braziliensis or L. panamensis/guyanensis infection were treated and cured without systemic therapy.
Although the stepwise approach validated here optimizes the use of the existing armamentarium, the improvement of this latter remains an essential goal. Current treatment guidelines display a strong synergism with the emergence of a new formulation of topical aminoglycosides for the treatment of L. major CL [28, 51] . When available, this third-generation topical aminoglycoside ointment will replace simple wound care and Cryo + IlSb, thus resulting in further simplification of treatment strategies. In addition, because it is simpler to apply a cream than to perform Cryo + IlSb, the proportion of patients treated topically will surely grow compared to that of patients receiving systemic treatments. Only lesions of eyelids, lips, genitalia, and mucosae are ineligible for topical therapy, that is, 10% of lesions in our experience (Figure 3) . A vast majority of patients will thus benefit from this inexpensive approach. Further evaluations of topical aminoglycoside formulations in CL due to other Old World and New World species are ongoing or planned [51] .
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